# US 2008/0188433 A1 · Methods of diagnosis of spinal muscular atrophy and treatments thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0188433 A1
- Document ID: US20080188433A1
- Status: Published application
- Kind: A1
- Application number: 11/703,809
- Filed: 2007-02-07
- Published: 2008-08-07
- Earliest claimed: 2007-02-07
- Assignees: Academia Sinica
- Inventors: Hung Li
- Web page: https://patentgrep.com/patent/US20080188433A1

## CPC

- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- G01N 33/6872: {Intracellular protein regulatory factors and their receptors, e.g. including ion channels}
- G01N 2333/82: Translation products from oncogenes
- G01N 2500/02: Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Methods for treating SMA in a subject comprise administering to the subject a recombinant genetic vector comprising at least one copy of a Stathmin inhibitor. The inhibitor can be a Stathmin expression inhibitor. The inhibitor can be or can encode an antisense or RNAi nucleic acid, such as a siRNA or a shRNA. The copy can be a copy of a host-expressible Stathmin inhibitor or a copy of a host-expressible Stathmin expression inhibitor. Screening methods can comprise the following steps: providing a Stathmin binding agent and a cellular sample from a human subject at least suspected of either having SMA or having a low SMN protein-based condition; contacting the Stathmin binding agent with the cellular sample under conditions in which the agent can specifically bind to Stathmin present in the sample to form complexes, and removing non-specifically bound agent therefrom to leave remaining complexes, and detecting remaining complexes and comparing the level of complexes detected or of the corresponding Stathmin concentration that is present in the sample, to a control level determined from a healthy cellular sample. The detection of an elevated level of complexes or of Stathmin concentration provides a positive screening result.

## Claims

### Claim 1

A method for treating spinal muscle atrophy (SMA) in a human subject, the method comprising administering to said subject a recombinant genetic vector comprising a copy of a Stathmin inhibitor.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the inhibitor is a Stathmin expression inhibitor.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the copy is a copy of a host-expressible Stathmin inhibitor.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the copy is a copy of a host-expressible Stathmin expression inhibitor.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the inhibitor is or encodes an antisense or RNAi nucleic acid.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the inhibitor encodes an RNAi nucleic acid.

### Claim 7 (depends on 6)

The method according to claim 6, wherein the RNAi nucleic acid is a siRNA or a shRNA.

### Claim 8 (depends on 5)

The method according to claim 5, wherein the target sequence of the antisense or RNAi nucleic acid is CGT TTG CGA GAG AAG GAT A (SEQ ID NO: 6).

### Claim 9 (depends on 1)

The method according to claim 1, wherein the vector is a viral vector.

### Claim 10 (depends on 9)

The method according to claim 9, wherein the viral vector is an adenoviral, adeno-associated viral, herpes viral, or lentiviral vector.

### Claim 11

A screening method for use in diagnosis of SMA or a low-SMN protein-based condition, the method comprising
(A) providing a Stathmin binding agent and a cellular sample from a human subject at least suspected of either having SMA or having a low SMN protein-based condition.
(B) contacting the Stathmin binding agent with the cellular sample under conditions in which the agent can specifically bind to Stathmin present in the sample to form complexes, and removing non-specifically bound agent therefrom to leave remaining complexes, and
(C) detecting remaining complexes and comparing the level of complexes detected or of the corresponding Stathmin concentration that is present in the sample, to a control level determined from a healthy cellular sample,
whereby detection of an elevated level of complexes or of Stathmin concentration provides a positive screening result.

### Claim 12 (depends on 11)

The method according to claim 11, wherein the Stathmin binding agent is an anti-Stathmin antibody.

### Claim 13 (depends on 11)

The method according to claim 11, wherein the Stathmin binding agent is a detectably labeled Stathmin binding agent.

### Claim 14 (depends on 11)

The method according to claim 11, wherein the screening result is combined with a further test result in order to provide a diagnosis of SMA or a low-SMN protein-based condition.

### Claim 15 (depends on 11)

The method according to claim 11, wherein the further test result comprises a result of a test for functional SMN protein expression level, a result of a test for nuclear gem occurrence level, a result of a test for snRNP formation levels, or a combination thereof.

### Claim 16

A kit for use in a screening method for SMA or a low-SMN protein-based condition, the kit comprising a Stathmin binding agent and instructions for the use thereof to screen for an elevated Stathmin concentration.

### Claim 17 (depends on 16)

The kit according to claim 16, wherein the Stathmin binding agent is an anti-Stathmin antibody.

### Claim 18 (depends on 16)

The kit according to claim 16, wherein the Stathmin binding agent is a detectably labeled Stathmin binding agent.

### Claim 19 (depends on 16)

The kit according to claim 16, wherein the instructions further comprise instructions for combining said screening result with a further test result in order to provide a diagnosis of SMA or a low-SMN protein-based condition.

### Claim 20 (depends on 16)

The kit according to claim 16, wherein the further test result comprises a result of a test for functional SMN protein expression level, a result of a test for nuclear gem occurrence level, a result of a test for snRNP formation levels, or a combination thereof.
